The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder
Open accessAbstract
Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PKC inhibitor tamoxifen enhances the capacity of lithium to reduce symptoms of mania in BD [105–107].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [105]
In the citing paper
“Treatment of BD patients with lithium or valproate inhibits PKC upregulation, normalizing its level to that of euthymic subjects, and increases BDNF levels [105].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
The extended protein kinase C superfamily
MELLOR, H., & Parker, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,539
Baum, A. E., Akula, N., Cabanero, M., Cardona, I., Corona, W., Klemens, B., Schulze, T. G., Cichon, S., Rietschel, M., Nöthen, M. M., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002012 · Cited by 700
Takai, Y., Kishimoto, A., Inoue, M., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41009-x · Cited by 595
The Protein Kinase C Family for Neuronal Signaling
Tanaka, C., & Nishizuka, Y. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.003003 · Cited by 543
Papp, M., Willner, P., & Muscat, R. (1991) · Psychopharmacology · doi:10.1007/bf02244188 · Cited by 542
The role of protein kinase C activation and the vascular complications of diabetes
Daş-Evcimen, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 503
Research works printed but not linked: 3
- Birnbaum, 2004, Science, 306, 882, 10.1126/science.1100021 · DOI · Paper page
- Lenox, 1996, J Clin Psychiatry, 57, 23
- Goldstein, 1986, J Clin Psychiatry, 47, 153
Cited by
Sorted by citations
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Protein kinase C, an elusive therapeutic target?
Mochly‐Rosen, D., Das, K., & Grimes, K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 583
Potential Mechanisms of Action of Lithium in Bipolar Disorder
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0039-0 · Cited by 484
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Probing the Biology of Natural Products: Molecular Editing by Diverted Total Synthesis
Szpilman, A. M., & Carreira, E. M. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904761 · Cited by 221
Metadata
- Authors
- Zarate, C. A., & Manji, H. K.
- Affiliations
- National Institutes of Health (US)
- National Institute of Mental Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- CNS Drugs
- Published
- 2009-07
- Volume
- 23
- Issue
- 7
- Pages
- 569-582
- ISSN
- 1172-7047 (ISSN-L)
- PMC
- PMC2802274
- OpenAlex
- W2139699538
- Cited by
- 122
- References
- 80
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 7 · 2019: 10 · 2018: 5 · 2017: 13 · 2016: 6 · 2015: 6 · 2014: 10 · 2013: 7 · 2012: 12
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (Z01MH002830)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- protein kinase C, PKC inhibitors, bipolar disorder, mania, lithium, valproic acid, tamoxifen, targeted therapy, genome-wide association study
- MeSH terms
- Animals, Bipolar Disorder, Clinical Trials as Topic, Humans, Models, Biological, Protein Kinase C, Antimanic Agents, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
